Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active
More on the benefits of probiotics. Read here.
In total, 63% of patients receiving BB536 showed clinical remission (UC disease activity index [UCDAI] ≤ 2) at week 8 compared to 52% of those receiving placebo (P=0.395).
The authors observed a significant decrease of UCDAI scores (3.5±1.9 at baseline to 2.5±1.7 at week 8) in the BB536 group (P<0.01), while there was no significant decrease in the placebo group (P=0.88).
There was also a significant decrease in the Rachmilewitz endoscopic index (EI) and the Mayo sub-score at week 8 in the BB536 group, while there was no significant decrease in the placebo group.
Besides the single patient in the BB536 group who complained of a mild side effect, no other adverse effects were observed.
